| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net increase (decrease) in cash and cash equivalents | 494 | 2,108 |
| Cash and cash equivalents at beginning of period | 30,321 | - |
| Cash and cash equivalents at end of period | 30,815 | - |
Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (IRD)